BeyondSpring Says FDA Granted Fast Track To Plinabulin Plus Docetaxel In Lung Cancer; Agrees To Sell Majority Of China Unit To Biolin, Which Will Fund China Phase 3 Enrollment

Loading news article.

BeyondSpring Says FDA Granted Fast Track To Plinabulin Plus Docetaxel In Lung Cancer; Agrees To Sell Majority Of China Unit To Biolin, Which Will Fund China Phase 3 Enrollment | WAPE

BeyondSpring Says FDA Granted Fast Track To Plinabulin Plus Docetaxel In Lung Cancer; Agrees To Sell Majority Of China Unit To Biolin, Which Will Fund China Phase 3 Enrollment

Article summary

Related companies

Comments —